Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered significant bleeding events. Pharmaceutical companies, including the makers of Xarelto, have a duty to make sure that their drugs are reasonably secure for use – and failure to perform so might be grounds for compensation. Our lawyers are working tough to get those hurt by the drug the compensation they are entitled to.
Whilst bleeding is a widespread complication related with anticoagulants, it has been alleged that Xarelto is a lot more harmful than conventional blood thinners since no antidote exists to reverse its blood-thinning effects. This means that, in the event of an emergency, individuals might be at threat for irreversible bleeding difficulties, which includes site life-threatening internal and gastrointestinal hemorrhaging.
In case you or possibly a loved 1 suffered a critical bleeding event following taking Xarelto, you may have legal recourse. For much more info, make contact with us today to have your case reviewed, free of charge of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are seeking compensation from Bayer and Janssen for past and future healthcare bills, lost wages, pain and suffering and, in situations of death, funeral expenditures. In addition, they’re seeking punitive damages, that are generally awarded to punish the defendant and deter other companies from acting similarly.
Why Are Lawsuits Getting Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is harmful and defective. The plaintiffs claim that, unlike standard anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding in the occasion of an emergency. Plaintiffs inside the lawsuits allege critical and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a safe anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user within the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to severe bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing unsafe clotting.
Visit this page for much more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.